Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Biogen, Inc. (“Biogen”) (NASDAQ: BIIB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Biogen securities between October 22, 2019, and November 6, 2020, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/biib. This

BIIB Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Biogen, Inc. Investors of Class Action and Encourages Investors to Contact the Firm

The company has several interesting companies on its short list.

What to Expect From Biogen's $2.3 Billion Shopping Spree

SAN DIEGO--(BUSINESS WIRE)---- $BIIB #Alzheimers--Biogen Inc. (BIIB) Misled the Public and Investors Regarding the Viability of its Alzheimer's Drug Aduhelm

Shareholder Alert: Robbins LLP Reminds Investors Biogen, Inc. (BIIB) is Being Sued for Misleading Shareholders

Biogen may represent a very long-term buy.

2 Reasons to Buy Biogen, 1 Reason to Sell

NEW YORK--(BUSINESS WIRE)-- #Biogen--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Biogen, Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB) in the United States District Court for the District of Massachusetts on behalf of all persons and entities who purchased or otherwise acquired Biogen securities between June 7, 2021 and January 11, 2022, both dates included, (the “Class Period”). Investors have until

BIOGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Biogen, Inc. and Encourages Investors to Contact the Firm

SAN DIEGO--(BUSINESS WIRE)---- $BIIB #Aduhelm--Biogen Inc. (BIIB) Misled the Public and Investors Regarding the Viability of its Alzheimer's Drug Aduhelm

CORRECTING and REPLACING Shareholder Alert: Robbins LLP Informs Investors Biogen, Inc. (BIIB) is Being Sued for Misleading Shareholders

Shareholder Alert: Robbins LLP Informs Investors Biogen, Inc. (BIIB) is Being Sued for Misleading Shareholders

San Diego, California--(Newsfile Corp. - February 8, 2022) - Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB) who purchased Biogen common stock between June 7, 2021 and January 11, 2022, both dates inclusive (the "Class Period"). To serve as lead plaintiff in this class action, you must move the Court no later than April...

(BIIB) NEWS: Did you Suffer a Substantial Loss? Contact Johnson Fistel About Leading Biogen Inc. Class Action Lawsuit

NEW YORK, Feb. 8, 2022 /PRNewswire/ -- Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB) common stock between June 7, 2021 and January 11, 2022, inclusive (the "Class Period"). The lawsuit was filed in the United States District Court for the District of Massachusetts and alleges violations of the Securities Exchange Act of 1934.

BIOGEN INC. (NASDAQ: BIIB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc. (NASDAQ: BIIB)

Biogen (BIIB) signs an agreement with Xbrane Biopharma for exclusive global rights to the latter's biosimilar candidate, Xcimzane, referencing UCB's arthritis drug, Cimzia.

Biogen (BIIB) Inks Agreement to Add New Biosimilar Candidate

Biogen Inc BIIB and Xbrane Biopharma AB have entered into a license agreement to develop, manufacture, and commercialize Xcimzane, a preclinical monoclonal antibody, a proposed biosimilar referencing UCB SA's UCBJY Cimzia (certolizumab pegol) Get the Inside Access Traders Are Using to Profit More and Win Bigger. Don't Miss Out on Benzinga Pro!

Biogen-Xbrane Enter License Agreement For Cimzia Referenced Biosimilar, Xcimzane

Biosimilars have the potential to broaden patient access to effective and more affordable treatments and generate healthcare savings Biosimilars have the potential to broaden patient access to effective and more affordable treatments and generate healthcare savings

Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA® (Certolizumab pegol) with the Potential to Treat Rheumatoid Arthritis

The Federal Trade Commission (FTC) and the Securities and Exchange Commission (SEC) have launched two separate investigations into Biogen Inc BIIB and its Alzheimer's med, Aduhelm (aducanumab). Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Biogen's Aduhelm Approval, Marketing Comes Under FTC, SEC Probes

Shares of Biogen Inc. BIIB, -2.13% tumbled 2.2% in premarket trading on Friday after the company disclosed in a securities filing that it received a civil investigative demand from the Federal Trade Commission and an inquiry from the Securities and Exchange Commission in relation to Aduhelm, its new Alzheimer's disease drug. The SEC inquiry is requesting information about the sites that administer the drug, the regulatory approval, and Biogen's marketing for the therapy, the company said.

Biogen facing civil demand from FTC, inquiry from SEC about Alzheimer's drug

The U.S. antitrust regulator has asked Biogen Inc to present documents related to the approval and marketing of its Alzheimer's disease treatment, the drugmaker disclosed in a filing.

Biogen says U.S. FTC probing Alzheimer's disease drug

Biogen (BIIB) beats fourth-quarter estimates for both earnings and sales. The stock declines on weak sales and earnings guidance for 2022.

Biogen (BIIB) Q4 Earnings Top, Stock Down on Weak 2022 View

Biogen Inc. (BIIB) CEO Michel Vounatsos on Q4 2021 Results - Earnings Call Transcript

Biogen Inc BIIB posted Q4 sales of 2.73 billion, beating the consensus of $2.62 billion, down 4.2% Y/Y. Thousands of new traders are learning the ins and outs on how to find profitable trades every day with Benzinga Trading School.

Biogen's Alzheimer's Drug Clocks Q4 Sales Of Just $1M, FY22 Earnings Guidance Below Consensus

The shares of Biogen Inc (NASDAQ:BIIB) are down 5% to trade at $213.70 at last check, as the company's bleak 2022 forecast weighs.

Biogen Stock Hits 5-Year Low After Weak Forecast

Biogen Inc. (BIIB) delivered earnings and revenue surprises of 2.11% and 4.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Biogen Inc. (BIIB) Q4 Earnings and Revenues Surpass Estimates

Biogen Inc BIIB is trading lower Thursday morning after the company announced worse-than-expected fourth-quarter earnings results and issued guidance below estimates. Biogen reported quarterly revenue of $2.73 billion, which beat the estimate of $2.62 billion.

Why Biogen Shares Are Sliding Today

Shares of Biogen Inc. BIIB, -1.92% were down 3.7% in premarket trading on Thursday after missing earnings and revenue expectations in the final quarter of 2021. Biogen had earnings of $368.2 million, or $2.51 per share, in the fourth quarter of 2021, compared with $357.9 million, or $2.33 per share, in the fourth quarter a year ago.

Biogen's stock falls 3.7% on earnings miss, says it brought in $1 million in sales of Alzheimer's drug in the fourth quarter

Biogen Inc on Thursday forecast 2022 adjusted earnings well below analysts' estimates, as it expects minimal sales from its Alzheimer's drug following the U.S. Medicare regulator's move to limit coverage of the treatment.

Biogen 2022 profit forecast misses estimates on Aduhelm woes

Biogen Inc BIIB has exercised its option to participate in the development and commercialization of mosunetuzumab, a CD20xCD3 T-cell engaging bispecific antibody for B-cell non-Hodgkin's lymphoma (NHL), including follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL).  [LIVE NOW ON YOUTUBE] Click Here to Watch a FREE MASTERCLASS on the Ultimate Bear Market Survival Guide with Matt Maley!

Biogen Exercises Option To Participate Developing Genentech's Bispecific Antibody, Mosunetuzumab

CAMBRIDGE, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that it exercised its option to participate in the development and commercialization of mosunetuzumab. Biogen will pay a $30 million one-time option fee to Genentech, a member of the Roche Group, as part of the companies' long-standing collaboration on antibodies targeting CD20.

News for Biogen Stock (BIIB)